Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.01 | N/A | -13.23% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.01 | N/A | -13.23% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concern over current market conditions and the impact on financial performance. They reiterated their commitment to advancing their pipeline despite setbacks.
Management acknowledged the challenges faced during the quarter.
They emphasized the need for continued focus on product development.
Crinetics Pharmaceuticals reported a wider-than-expected loss in EPS, which contributed to a 3.18% decline in stock price following the earnings announcement. The lack of revenue figures and guidance may raise concerns among investors about the company's financial health and future prospects. Management's defensive tone suggests they are navigating challenges that could impact growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CONSTELLATION ENERGY
Nov 6, 2023